Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels

FASEB Journal

Volumn 13, Issue 15, 1999, Pages 2277-2283

  Jakubowski, Hieronim ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Homocysteine thiolactone

Indexed keywords

HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; METHIONINE TRANSFER RNA LIGASE; PLASMA PROTEIN; TRYPSIN;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; ENZYME INACTIVATION; HUMAN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; VASCULAR DISEASE;

EID: 0032778517     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.13.15.2277     Document Type: Article

References (20)

1. Jacobsen, D. W. (1998) Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 44, 1833-1843
2. Jakubowski, H. (1990) Proofreading in vivo: Editing of homocysteine by methionyl-tRNA synthetase in Escherichia coli, Proc. Natl. Arad. Sci. USA 87, 4504-4508
3. Jakubowski, H. (1991) Proofreading in vivo: Editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. EMBO J. 10, 593-598
4. Jakubowski, H., and Goldman, E. (1993) Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 317, 593-598
5. Gao, W., Goldman, E., and Jakubowski, H. (1994) Role of carboxy terminal region in proofreading function of methionyl-tRNA synthetase in Escherichia coli. Biochemistry 33, 11528-11535
6. Jakubowski, H. (1995) Proofreading in vivo: Editing of homocysteine by aminoacyl-tRNA synthetases in Escherichia coli. J. Biol. Chem. 270, 17672-17673
7. Jakubowski, H. (1997) Metabolism of homocysteine thiolactone in human cell cultures: Possible mechanism for pathological consequences of elevated homocysteine levels. J. Biol. Chem. 272, 1935-1942
8. Jakubowski, H., and Fersht, A. (1981) Alternative pathways of rejection of noncognate amino acids by aminoacyl-tRNA synthetases. Nucleic Acids Res. 9, 3105-3117
9. Jakubowski, H. (1997) Aminoacyl thioester chemistry of class II aminoacyl-tRNA synthetases. Biochemistry 36, 11077-11085
10. Baernstein, H. D. (1934) A modification of the method for determining methionine in proteins. J. Biol. Chem. 106, 451-456
11. Ausubel, F. M. (1990) Current Protocols in Molecular Biology, Vol. II, Wiley & Sons, New York
12. Dudman, N. P. B., Hicks, C., Lynch, J. F., Wilcken, D. E. L., and Wang, J. (1991) Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler. Thromb. 11, 663-670
13. Bergemeyer, H. U., Gavehn, K., and Grassl, M. (1974) In Methods of Enzymatic Analysis, Vol. I 2nd edition (Bergemeyer, H. U., ed.) pp. 515-516, Academic Press, New York
14. Liu, G., Nellaiappan, K., and Kagan, H. M. (1997) Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. J. Biol. Chem. 272, 32370-32377
15. Ferguson, E., Parthasarathy, S., Joseph. J., and Kalyanaraman, B. (1998) Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein. J. Lipid Res. 39, 925-933
16. Hawkins, D., Pinckard, R. N., Crawford, I. P., and Farr, R. S. (1969) Structural changes in human serum albumin induced by ingestion of acetylsalicylic acid. J. Clin. Invest. 48, 536-542
17. Yvon, M., and Wal, J. M. (1988) Identification of lysine residue 199 of human serum albumin as a binding site for benzylpenicilloyl groups. FEBS Lett. 239, 237-240
18. Booth, A. A., Khalifah, R. J., Todd, P., and Hudson, B. G. (1997) In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem. 272, 5430-5437
19. Harrington, C. R., and Colaco, C. A. L. S. (1994) Alzheimer's disease: A glycation connection. Nature (London) 370, 247-248
20. Holvoet, P., Perez, G., Zhao, Z., Brouwers, E., Bernar, H., and Collen, D. (1995) Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95, 2611-2619